ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease

OPKO Health

Status and phase: Completed; Phase 2

Conditions: Alzheimer's Disease

Treatments: Drug: ELND005 (scyllo-inositol)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00934050

ELND005-AD251

Details and patient eligibility

About

The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.

Enrollment: 103 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• This study is open only to subjects who have completed the week 78 visit in Study ELND005-AD201 while taking their assigned dose of study drug medication.

Exclusion criteria

• Subject has no new medical contraindications to continued participation in the study.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

103 participants in 1 patient group

ELND005

Experimental group

Treatment:

Drug: ELND005 (scyllo-inositol)